Galien, H. V. D., Mutsaers, P., Jak, M., Poel, M. V. D., Nijk, M., Meijer, K., Tienstra, M., Keijzer, K., Boer, J. D., Demandt, A., Vledder, A., Spanjaart, A., Pennings, E., Kuipers, M., Kersten, M. J., Doesum, J. V., Niezink, A., Vermaat, J., Dorp, S. V., Meerten, T. V. (2025). Transformed FL shows improved survival after CAR T-cell therapy compared to de novo LBCL, but early transformation (<12 months) defines a poor-risk subgroup: Results from a nationwide cohort. Blood. https://doi.org/10.1182/blood-2025-959